Mass General to Test Mallinckrodt’s Nitric Oxide as a COVID-19 Treatment

Massachusetts General Hospital will conduct a clinical trial of Mallinckrodt’s INOmax (nitric oxide) for treatment of low blood oxygen levels in patients with severe COVID-19 lung complications.

Mallinckrodt previously received approval from Health Canada for a trial of high-dose inhaled nitric oxide therapy to treat COVID-19 infections and associated lung complications.

The company said more than 170 hospitals and health systems in the U.S. have used INOmax as an experimental treatment for pulmonary complications in COVID-19 patients.